Biotech: Biologics and cell therapy products

3P Biopharmaceuticals has the GMP (Good Manufacturing Practices) certification issued by the AEMPS for the manufacture and release of biological active substances, the release of biological drugs and the release of sterile products for both human and veterinary use and for the manufacture and release of cell therapy product: human allogeneic adult stem cells extracted from hearth tissue an "in vitro“ expanded.

Last year, 3P attended a total of 11 events, participating in three of them as exhibitors: Bio International Convention, CPhI and Biolatam, where our scientific director, Edita Mistiniene, presented a conference in the biosimilars session.

As part of the strategic commitment of our company to the development of biosimilars, 3P will attend the “4th Biosimilars Congregation” and the “7th Annual Antibodies & Proteins / Biosimilars & Biobetters” Congress. The development of processes and the production of biosimilars are now a priority for the company, although process development projects linked to production, industrial scaling and GMP production of new biological molecules remain the main driver of the company.

Meanwhile, the Cell Therapy Area, continuing its strategy of international expansion, is scheduled to attend two international events in advanced therapies and regenerative medicine for the second half of the year. The area of ​​cell therapy in 3P is currently working on developing a tissue engineered product for the treatment of vitiligo, and several R + D + i for the generation of intermediate products in the field of cell therapy and tissue engineering.